SEC filings and other documents

Scaling robotics and AI-powered rehab with strong reimbursement and global reach.

Q2 2026 revenue up 16% to $6.6M; net loss widens on non-cash charges; cash position strengthened.

Q1 revenue fell on AlterG delays, but ReWalk sales and liquidity improved with new acquisitions.

Strategic shift and new partnerships drive innovation, efficiency, and expanded market access.

Record ReWalk placements and improved margins drive Q3 growth, with strong outlook reaffirmed.

Q2 revenue rose sequentially, guidance reset, and operational efficiencies improved.

Innovative rehab tech, expanding coverage, and strong growth forecast drive a $1.75B market.

Positioned for growth with innovative rehab tech, expanding coverage, and profitability targeted for 2026.

Revenue grew on a comparable basis, margins improved, and full-year guidance was reaffirmed.

Record revenue, margin improvement, and new partnerships set the stage for 2025 growth.

Q3 revenue up 39% with improved margins and strong ReWalk and AlterG pipelines.

Revenue up 402% year-over-year, with record ReWalk placements and improved margins.

Medicare-backed ReWalk growth drove Q1 revenue up 340% YoY to $5.3M.